title: Optimal debulking surgery is an independent prognostic factor in patients with FIGO IIIC primary epithelial ovarian carcinoma.
abstract: BACKGROUND
  Ovarian cancer is a well-known disease with a poor prognosis. Due to the relatively small number of cases in Taiwan, the outcome and prognostic factors of patients with primary epithelial ovarian carcinoma are unknown.
  
  
  METHODS
  We retrospectively studied patients with proven surgical and pathologic (Federation Internationale de Gynecologie et d'Obstetrique) FIGO IIIC primary epithelial ovarian carcinoma. All patients underwent standard staging surgery, including washing cytology, total abdominal hysterectomy, bilateral salpingo-oophorectomy, retroperitoneal lymphadenectomy, infracolic omentectomy and excisional biopsy of all suspicious lesions followed by adjuvant chemotherapy with four to 12 courses of cyclophosphamide, epirubicin and cisplatin (CEP) or cyclophosphamide, adriamycin and cisplatin (CAP) intravenously, every three weeks. To avoid the coeffects of chemotherapy and surgical procedures upon the outcome, patients who received paclitaxel-based regimens or underwent incomplete surgery were excluded. Ninety-eight patients from 1990 to 1996 were identified.
  
  
  RESULTS
  The mean follow-up time was 28.7 months, ranging from 5.4 months to 105.9 months. The cumulative five-year disease-free survival rate for all patients was 31.6%. Optimal debulking surgery was completed in 41.8% of patients, which contributed to long-term patient survival (54% vs 16%, p < 0.0001), compared to patients without optimal debulking surgery. Optimal debulking surgery was the only statistically significant independent prognostic factor for five-year disease-free survival using multivariate analysis.
  
  
  CONCLUSIONS
  To improve survival of patients with FIGO stage IIIC epithelial ovarian carcinoma, optimal debulking surgery should be performed as the initial form of surgical intervention.
authors.affiliation: Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taiwan, ROC.
authors.forename: P H
authors.initials: PH
authors.lastname: Wang
authors.forename: C C
authors.initials: CC
authors.lastname: Yuan
authors.forename: W Y
authors.initials: WY
authors.lastname: Shyong
authors.forename: S C
authors.initials: SC
authors.lastname: Chiang
authors.forename: J Y
authors.initials: JY
authors.lastname: Chao
authors.forename: M S
authors.initials: MS
authors.lastname: Yen
authors.forename: H T
authors.initials: HT
authors.lastname: Ng
mesh_terms: D018394:CA-125 Antigen / Q000097:blood; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D018394:CA-125 Antigen